Crescent Biopharma announces FDA clearance of IND application for CR-002
CBIO•Crescent Biopharma said the FDA cleared its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumors. The company expects initial Apollo trial data in the second half of 2027 and plans to start the Phase 1/2 global trial in Q4 2026.
1. CR-002 trial plans
Crescent Biopharma said the FDA cleared its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor antibody-drug conjugate for solid tumors. The company plans to initiate the Apollo Phase 1/2 global trial in Q4 2026 and expects initial clinical data in the second half of 2027.
